Loading COR detail
Loading ticker data...
Loading COR detail
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally.
The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023.
Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
Chart data unavailable
KindlyMD (NASDAQ: NAKA - Get Free Report) and Cencora (NYSE: COR - Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation. Profitability This table compares KindlyMD and Cencora's net margins, return
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2026 on Wednesday, May 6, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 6, 2026. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Fin.
Allspring Global Investments Holdings LLC reduced its position in Cencora, Inc. (NYSE: COR) by 9.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 383,068 shares of the company's stock after selling 40,638 shares during the quarter. Allspring Global Investments Holdings LLC owned
Cencora is acquiring EyeSouth's retina business for $1.1 billion, expanding its RCA platform to strengthen foothold in the fast-growing eye care market.
Drug distributor Cencora said on Monday it would buy the retina business of eye care network EyeSouth Partners for $1.1 billion, expanding its eye care unit.
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced the signing of a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. Upon completion of the transaction, the affiliated retina physicians of EyeSouth Partners will join Cencora's Retina Consultants of America (“RCA”), a leading management services organization (MSO). “Driven by a commitment to empower ophthalmologists, EyeSouth Partners has built a strong regional network of physicians.
Cencora's strong U.S. growth, MSO strategy, and raised outlook support long-term potential, but competition and customer losses remain key risks.
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that James F. Cleary will retire as Executive Vice President and Chief Financial Officer effective June 30, 2026. Cencora has engaged an executive search firm to identify and evaluate potential successors from internal and external candidates. Mr. Cleary will assist in the search process and will serve in an advisory capacity through the end of 2026 to help ensure a smooth transition. Mr. Cleary, 62, has served as Cen.
California Public Employees Retirement System lowered its stake in Cencora, Inc. (NYSE: COR) by 13.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 588,788 shares of the company's stock after selling 93,334 shares during the quarter. California Public Employees Retirement
Chilton Investment Co. Inc. acquired a new stake in shares of Cencora, Inc. (NYSE: COR) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,468 shares of the company's stock, valued at approximately $459,000. Other hedge funds and other
Alliancebernstein L.P. lowered its position in Cencora, Inc. (NYSE: COR) by 21.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 889,802 shares of the company's stock after selling 244,496 shares during the period. Alliancebernstein L.P. owned 0.46% of Cencora worth
Glenmede Investment Management LP reduced its stake in Cencora, Inc. (NYSE: COR) by 2.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 169,665 shares of the company's stock after selling 4,232 shares during the quarter. Glenmede Investment Management
CreativeOne Wealth LLC reduced its stake in Cencora, Inc. (NYSE: COR) by 51.1% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,980 shares of the company's stock after selling 3,119 shares during the quarter. CreativeOne Wealth LLC's holdings in Cencora were worth
Cencora, Inc. (COR) Presents at Leerink Global Healthcare Conference 2026 Transcript
Cencora, Inc. (COR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
